Form 4: Sanara MedTech Director Sara N. Ortwein Reports Stock Grant and Disposal

Director Sara N. Ortwein reports receiving a grant of 3,440 shares of restricted stock and disposing of 17,522 shares of common stock.

Summary

• On June 12, 2024, Sara N. Ortwein, a director of Sanara MedTech Inc., reported a transaction involving the company's common stock.
• Ortwein acquired 3,440 shares of restricted stock granted under the Sanara MedTech Inc. 2014 Omnibus Long-Term Incentive Plan.
• These shares will vest on June 12, 2025, contingent upon Ortwein's continued service to the company.
• Ortwein also disposed of 17,522 shares of common stock.
• Following these transactions, Ortwein beneficially owns 17,522 shares of Sanara MedTech Inc.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but the disposal of shares could be viewed with slight caution.

Positives

• The grant of restricted stock to a director aligns their interests with the long-term performance of the company.

Negatives

• The disposal of 17,522 shares by a director could be interpreted negatively by the market, although the reason for disposal is not specified.

Risks

• The vesting of the restricted stock is contingent upon the director's continued service, creating a potential risk if the director were to leave the company before the vesting date.

Future Outlook

The vesting of the restricted stock on June 12, 2025, is contingent upon the director's continued service to the company.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock.

Stakeholder Impact

• Shareholders may be interested in the director's stock transactions as an indicator of their confidence in the company.

Key Dates